Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Neurology(R) neuroimmunology & neuroinflammation - 7(2020), 4 vom: 20. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahler, Christoph [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 13.09.2021 Date Revised 13.09.2021 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1212/NXI.0000000000000756 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310171318 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310171318 | ||
| 003 | DE-627 | ||
| 005 | 20231225135517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/NXI.0000000000000756 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310171318 | ||
| 035 | |a (NLM)32434801 | ||
| 035 | |a (PII)e756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mahler, Christoph |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2021 | ||
| 500 | |a Date Revised 13.09.2021 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Andrews, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Henson, Sian M |e verfasserin |4 aut | |
| 700 | 1 | |a Gnanapavan, Sharmilee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology(R) neuroimmunology & neuroinflammation |d 2014 |g 7(2020), 4 vom: 20. Juli |w (DE-627)NLM243009216 |x 2332-7812 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:4 |g day:20 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1212/NXI.0000000000000756 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |e 4 |b 20 |c 07 | ||